{"version":"1.0","type":"link","title":"Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.","author_name":"Yeo W 외","author_url":"https://prs-insight.online/author/Yeo%20W","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/169901","thumbnail_width":1200,"thumbnail_height":630}